Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Delivery SystemsDiabetesDiabetes Mellitus, Type 1
- Registration Number
- NCT00569998
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 208
Inclusion Criteria
- Type 1 or type 2 diabetes mellitus for at least 12 months
- Adults at least 18 years
- Children/adolescents between 9-18 years
- HbA1c lesser than or equal to 11.0%
Exclusion Criteria
- Known or suspected alcohol or drug abuse
- Patients who are not able to read the user manual (may wear glasses if needed)
- Hypoglycaemic unawareness as judged by the investigator
- Visual and/or dexterity impairments as judged by the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Evaluation of overall pen preference after 12 weeks of treatment
- Secondary Outcome Measures
Name Time Method Adverse device effects Adverse events HbA1c
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇬🇧Sidcup, United Kingdom